A Phase 1/2 interventional study of HP518 - Dose Escalation and HP518 - Dose Escalation in Metastatic Castration-resistant Prostate Cancer, sponsored by Hinova Pharmaceuticals Inc.. Recruiting at 27 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.
Sponsored by Hinova Pharmaceuticals Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 542 studies in Prostatic Neoplasms with a site in China — 281 open to participants now, 342 under way, 52 of them phase 3. Prostatic Neoplasms · China.
Among the 542 studies in Prostatic Neoplasms with a site in China, this one is the 240th largest by planned enrollment of the 436 interventional ones that give a count, is one of 59 that started in 2023, is one of 52 in phase 1/2, reaches primary completion later than 99 of the 341 other live ones, and was the 266th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →281 of the 542 studies in Prostatic Neoplasms with a site in China are open now. Recruiting first, the newest first:
Norroy Bioscience Co., LTD · Sites in China
Ages 18+ · Men only
The First Affiliated Hospital of Xiamen University · Sites in China
Ages 18+ · Men only
Yong He · Sites in China
Ages 18–90 · Men only
TransThera Sciences (Nanjing), Inc. · Sites in China
Ages 18+ · Men only
Janssen Research & Development, LLC · Sites in China, United States, Australia and 1 more country
Ages 18+ · Men only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
542 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 149 · Phase 2 146 · Phase 3 88 · Phase 4 7
First in 2003; this study’s year is marked. 59 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 84 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 100 across the 436 interventional studies, 300 across the 106 observational. Of the 110 that completed or were terminated, 23 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
200 of 542 have an industry lead sponsor. The 10 most frequent:
Hinova Pharmaceuticals Inc. is the lead sponsor of 8 studies on the registry; 5 are open to participants now.
Hinova Pharmaceuticals Inc. has 4 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
95 of the studies in Prostatic Neoplasms with a site in China that are under way reach primary completion within a year, 11 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03258320Phase 3Shanghai Jiao Tong University School of MedicineA Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients | 2026-12 |
| NCT04691804Phase 3Jiangsu HengRui Medicine Co., Ltd.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT06551324Phase 3PfizerA Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | 2027-02-28 |
| NCT07241416Phase 3Jiangsu HengRui Medicine Co., Ltd.A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer | 2027-03 |
| NCT02531516Phase 3Aragon Pharmaceuticals, Inc.An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS | 2027-03-01 |
Add all 95 to your calendar (.ics) → With an account.
Among the 542 studies in Prostatic Neoplasms with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall objective of this Phase 1 study is to evaluate the safety, PK,and anti-tumor activity of daily oral dosing with HP518,selecting the RP2D of HP518 based on assessments of patients with progressive mCRPC in dose-escalation phase
This First in Human dose escalation and expansion study of HP518 in patients with progressive mCRPC after NHA and chemotherapy is being conducted not only to evaluate the safety and tolerability of orally administered HP518, but also to provide preliminary efficacy for the reference of future studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral tablet(s), once daily in 28-day cycles
Drug: HP518 - Dose Escalation
Oral tablet(s), once daily in 28-day cycles
Drug: HP518 - Dose Escalation
Oral tablet(s), once daily in 28-day cycles
Drug: HP518 -Dose Expansion
Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort
Also known as: Part 1 - Dose Escalation
Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort
Also known as: Part 1 - Dose Escalation
Part 2: Dose expansion Daily oral dosage with the highest dose with acceptable toxicity (RP2D) based on data from Part 1.
Also known as: Part 2 - Dose Expansion Oral tablet(s)
Incidences of Protocol-defined DLT during the DLT assessment period , characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drugorally administered HP518 (Part 1)
To evaluate the safety and tolerability and determine the MTD and the RP2D of orally administered HP518 (Part 1)
Time frame: 28 DAYS
Incidence of Treatment-Emergent Adverse Events characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness
To evaluate the safety of orally administered HP518 (Part 1)
Time frame: Through study completion, an average of 1 year
Incidence of laboratory abnormalities, characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing
To evaluate the safety of orally administered HP518 (Part 1)
Time frame: Through study completion, an average of 1 year
Incidence of vital signs abnormalities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing
To evaluate the safety of orally administered HP518 (Part 1)
Time frame: Through study completion, an average of 1 year
Incidence of ECG (PR, QRS, QT, and QTcF intervals) abnormalities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing
To evaluate the safety of orally administered HP518 (Part 1)
Time frame: Through study completion, an average of 1 year
PSA50 response rate
Proportion of patients showing a PSA decline by ≥50% between baseline and Week 12 of dosing with HP518.
Time frame: 12 weeks
area under the concentration-time curve (AUC)
Assessment of pharmacokinetic parameters of HP518
Time frame: 12 weeks
Maximum concentration (Cmax)
Assessment of pharmacokinetic parameters of HP518
Time frame: 12 weeks
Time to maximum concentration (Tmax)
Assessment of pharmacokinetic parameters of HP518
Time frame: 12 weeks
Apparent terminal elimination half-life (T1/2)
Assessment of pharmacokinetic parameters of HP518
Time frame: 12 weeks
apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)
Assessment of pharmacokinetic parameters of HP518
Time frame: 12 weeks
oral clearance (CL/F)
Assessment of pharmacokinetic parameters of HP518
Time frame: 12 weeks
According to PCWG3
evaluate PSA50 response rate: PSA decline by≥50% between baseline and 4 weeks/8 weeks/12 weeks( only Part 1) of dosing with HP518
Time frame: 8 weeks
According to PCWG3, evaluate time to PSA progression
PCWG3 definition: PSA increase \>25% and \>2 ng/mL above nadir, confirmed by progression at 2 time points at least 3 weeks apart) nadir, confirmed by progression at 2 time points at least 3 weeks apart)
Time frame: Through study completion, an average of 1 year
Time to radiographic progression by investigator PCWG3 definition
using the RECIST v1.1 and PCWG3 definition
Time frame: Through study completion, an average of 1 year
Evaluate the modified best overall response mBOR by investigator
According to RECIST (version 1.1) and PCWG3
Time frame: Through study completion, an average of 1 year
analyze the efficacy of patients with different AR phenotypes(Part 2)
According to genetic testing results
Time frame: Through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Mar 2026, 27 months after the start.
Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 27 months is below that.
Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hinova Pharmaceuticals Inc.